EMERYVILLE, Calif.--(BUSINESS WIRE)--AllCells, LLC, today announced that it has completed the relocation and operational expansion of its Shanghai-based facilities.
AllCells-Shanghai is now situated in Ju Ke Park (聚科生物园区) near the center of the city with almost 10,000 sq. ft of laboratory, production and office space. The new facility is also equipped with GMP level cell culture rooms. AllCells’ Chief Executive, Jay Tong, MD commented, “The Ju Ke Biotechnology Park location not only provides the larger space that is essential for supporting the company’s continuing growth, but also enables us have access to better and highly controlled bio-processing environments. This is a really important consideration for producing high quality primary cell products, tissues, and services that our customers depend upon for their biomedical applications.”
AllCells-Shanghai is currently recruiting individuals to fill several open positions in the areas of Sales & Marketing / Business Development, Production, and Operations Management. Refer to the Careers section of www.AllCells.com for more information.
About AllCells, LLC
AllCells (www.AllCells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements.
AllCells-Shanghai facilities produce animal derived primary cell types including bone marrow mononuclear cells, stromal cells, immunological, splenocytes, pancreatic islets, neural system (astrocytes, meningeal cells), and others. The company’s products are used in routine cell-based assays for compound screening, predictive toxicology, and other research applications that enable pre-clinical drug development. Additionally, the company plans to expand its service offering to include hematopoietic stem cell expansion & differentiation, flow-cytometry services (e.g. comprehensive FACS analysis, up to 11 colors), immunophenotyping, in-vitro characterization of malignant cells (e.g. leukemia, myeloma, lymphoma, etc.), custom cell-based assays, and validation studies involving cell/tissue separation devices for laboratory or clinical use by importing AllCells-USA made human primary cells.